Cargando…

Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings

OBJECTIVE: This study aims to systematically validate the performance of surrogate endpoints in phase II and III clinical trials for NSCLC patients under various trial settings. METHODS: A literature search retrieved all registered phase II and III trials of NSCLC patients in which OS, with at least...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hua, Tiantian, Gao, Yuan, Zhang, Ruyang, Wei, Yongyue, Chen, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520950/ https://www.ncbi.nlm.nih.gov/pubmed/36171546 http://dx.doi.org/10.1186/s12885-022-10046-z

Ejemplares similares

Endpoint surrogacy in oncology Phase 3 randomised controlled trials
por: Zhang, Jianrong, et al.
Publicado: (2020)

TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
por: Roeper, Julia, et al.
Publicado: (2020)

Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy
por: Buyse, Marc, et al.
Publicado: (2022)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)
por: Lassere, Marissa N, et al.
Publicado: (2012)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
por: Jeeyapant, Atthanee, et al.
Publicado: (2017)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
por: Bikdeli, Behnood, et al.
Publicado: (2017)

Binary surrogate endpoints in clinical trials from the perspective of case definitions
por: HAHN, ANDREAS, et al.
Publicado: (2021)

A call for better reporting of trials using surrogate primary endpoints
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
por: Ciani, Oriana, et al.
Publicado: (2023)

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints
por: Pitcher, Alex, et al.
Publicado: (2011)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
por: Krendyukov, Andriy, et al.
Publicado: (2021)

Commentary on: A call for better reporting of trials using surrogate primary endpoints
por: Cummings, Jeffrey
Publicado: (2022)

Appropriate Surrogate Endpoint in Drug-Coated Balloon Trials for Coronary Artery Diseases
por: Lang, Xinyue, et al.
Publicado: (2022)

Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials
por: Chamberlain, Jeffrey S., et al.
Publicado: (2023)

Surrogate mother – praiseworthy or stigmatized: a qualitative study on perceptions of surrogacy in Assam, India
por: Arvidsson, Anna, et al.
Publicado: (2017)

John Orr
Publicado: (1949)

The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China
por: Rui, Mingjun, et al.
Publicado: (2022)

A randomised controlled trial is not a pilot trial simply because it uses a surrogate endpoint
por: Campbell, M. J., et al.
Publicado: (2018)

Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers
por: Morel, Alix, et al.
Publicado: (2021)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials
por: Wang, An, et al.
Publicado: (2023)

Failed surrogate conceptions: social and ethical aspects of preconception disruptions during commercial surrogacy in India
por: Mitra, Sayani, et al.
Publicado: (2016)

Gay father surrogacy families: relationships with surrogates and egg donors and parental disclosure of children's origins
por: Blake, Lucy, et al.
Publicado: (2016)

Parents' relationship with their surrogate in cross-border and domestic surrogacy arrangements: comparisons by sexual orientation and location
por: Jadva, Vasanti, et al.
Publicado: (2019)

Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint
por: Nixon, Richard M, et al.
Publicado: (2003)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2094birkuth4hkl1l5j008oren